Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2014 1
2022 1
2023 5
2024 1
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation.
Kean LS, Burns LJ, Kou TD, Kapikian R, Lozenski K, Langston A, Horan JT, Watkins B, Qayed M, Bratrude B, Betz K, Tang XY, Zhang MJ, Connolly SE, Polinsky M, Gavin B, Gomez-Caminero A, Pasquini MC. Kean LS, et al. Among authors: lozenski k. Blood. 2024 Oct 24;144(17):1834-1845. doi: 10.1182/blood.2023023660. Blood. 2024. PMID: 39028876 Free PMC article.
Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials.
Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W. Dieudé P, et al. Among authors: lozenski k. Semin Arthritis Rheum. 2025 Oct;74:152795. doi: 10.1016/j.semarthrit.2025.152795. Epub 2025 Jul 16. Semin Arthritis Rheum. 2025. PMID: 40768904 Free article.
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials.
Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Gladman DD, et al. Among authors: lozenski k. Rheumatol Ther. 2026 Feb;13(1):213-229. doi: 10.1007/s40744-025-00812-3. Epub 2025 Dec 15. Rheumatol Ther. 2026. PMID: 41396391 Free PMC article.
Predicting abatacept retention using machine learning.
Alten R, Behar C, Merckaert P, Afari E, Vannier-Moreau V, Ohayon A, Connolly SE, Najm A, Juge PA, Liu G, Rai A, Elbez Y, Lozenski K. Alten R, et al. Among authors: lozenski k. Arthritis Res Ther. 2025 Feb 1;27(1):20. doi: 10.1186/s13075-025-03484-0. Arthritis Res Ther. 2025. PMID: 39893489 Free PMC article.
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.
Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Citera G, Huang KG, Wu C, Connolly SE, Elbez Y, Wong R, Lozenski K, Fleischmann R. Emery P, et al. Among authors: lozenski k. Arthritis Res Ther. 2023 Apr 22;25(1):67. doi: 10.1186/s13075-023-03038-2. Arthritis Res Ther. 2023. PMID: 37087459 Free PMC article. Clinical Trial.
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R, Tony HP, Bannert B, Nüßlein H, Rauch C, Connolly SE, Chartier M, Lozenski K, Hackl R, Forster A, Peichl P. Alten R, et al. Among authors: lozenski k. Clin Rheumatol. 2023 Sep;42(9):2321-2334. doi: 10.1007/s10067-023-06649-x. Epub 2023 Jun 14. Clin Rheumatol. 2023. PMID: 37314665 Free PMC article.
16 results